Trial · NCT02959554
Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
NCT02959554, Phase 2, Terminated, AIO-Studien-gGmbH
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control. Trials, record NCT02959554. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02959554
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
- NCT number
- NCT02959554
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 49 participants, actual
- Lead sponsor
- AIO-Studien-gGmbH
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Nivolumab, Sunitinib, Pazopanib
- First posted
- 2016-11-09
- Last updated
- 2021-09-08
- Other registries' IDs
- eudract:2016-002170-13
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival (OS) | 128 of events in max. 72 months | Efficacy measure |
| Secondary | Best overall response rate | From start of 1st line until disease progression or death of last patient (max. 72 months) | Best overall response (PR+CR) throughout the 1st-line treatment according to RECIST 1.1 |
| Secondary | Progression free survival (PFS) | 72 months | PFS time of randomization to death from any caused OS From start of 1st line TKI therapy |
| Secondary | Quality of Life | From randomization until disease progression or death of last patient (max. 72 months) | Health related-Quality of Life (Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI) FKSI-15 score and changes in the FKSI-15 score. |
| Secondary | Quality of Life | From randomization until disease progression or death of last patient (max. 72 months) | Proportion of subjects with increase from baseline in FKSI-15 (MID 3 points) |
| Secondary | Safety - Absolute and relative frequencies of emergent adverse events according to CTCAE 4.03 | From randomization until 100 days after end of treatment of last patient (post last dose). | Adverse Events (AEs) / Serious Adverse Events (SAEs) / Treatment Emergent Adverse Events according to CTCAE 4.03 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02959554
GET https://conductscience.org/api/trials/v1/NCT02959554/registered